| UCSF Protocol No. | ClinicalTrials.gov Protocol No. | PI Name | Title | |||
| Pediatric Cancers > Brain Tumors | ||||||
| 14083 | NCT02124772 | Mueller, Sabine | An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations | |||
| 18083 | NCT03749187 | Mueller, Sabine | A Target Validation/Phase1 Study of BGB-290 in Combination with Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas | |||
| 18086 | NCT03893487 | Mueller, Sabine | A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG) | |||
| 150812 | NCT02962167 | Mueller, Sabine | PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT) | |||
| 150814 | NCT02520713 | Sabnis, Amit | Multicenter Cohort Study To Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Solid Tumors: The iCat2, GAIN Consortium Study | |||
| 160825 | NCT03690869 | Mueller, Sabine | A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma | |||
| 160829 | NCT02909777 | Vo, Kieuhoa | Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | |||
| 170819 | NCT03330197 | Mueller, Sabine | A Phase I/II Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects | |||
| 180812 | Reddy, Alyssa | Telemedicine in Pediatric Neuro-Oncology Patients: A Feasibility and Pilot Randomized Control Trial | ||||
| 180823 | NCT03579602 | Mueller, Sabine | A randomized, blinded study of fluorescence detection of pediatric primary central nervous system tumors in subjects receiving tozuleristide and imaged with the Canvas System | |||
| ADVL1823 | NCT03834961 | Vo, Kieuhoa | Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias | |||
| Pediatric Cancers > Brain Tumors > Glioma | ||||||
| 160831 | NCT03429803 | Mueller, Sabine | A Phase I Study of TAK- 580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK/ Pathway Activated Tumors | |||
| 190815 | NCT04323046 | Mueller, Sabine | A Randomized, Double- Blinded, Pilot, Trail of Neoadjuvant Checkpoint Inhibition Followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Reccurrent or Progressive High Grade Glioma (HGG) | |||
| 190819 | NCT04485559 | Mueller, Sabine | A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low-Grade Gliomas | |||
| 150819 | NCT02960230 | Mueller, Sabine | H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC with and without PD-1 inhibition using Nivolumab for the Treatment of newly diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) and newly diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Gliomas | |||
| 160816 | NCT03086616 | Mueller, Sabine | PNOC009: A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging with Gadolinium in Children with Diffuse Intrinsic Pontine Glioma | |||
| 170817 | NCT03566199 | Mueller, Sabine | An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-Enhanced Delivery (CED) in Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated with External Beam Radiation Therapy | |||
| 170827 | NCT03739372 | Mueller, Sabine | A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with High Grade Glioma (Excluding Diffuse Intrinsic Pontine Glioma) | |||
| 180820 | NCT03416530 | Kline, Cassie | ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas | |||
| ACNS1723 | NCT03919071 | Reddy, Alyssa |
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) |
|||
| ACNS1833 | NCT04166409 | Reddy, Alyssa |
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low- Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) |
|||
| Pediatric Cancers > Brain Tumors > Medulloblastoma > Newly Diagnosed | ||||||
| ACNS1422 | NCT02724579 | Reddy, Alyssa | A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients | |||
| Pediatric Cancers > Phase 1 Clinical Trials | ||||||
| 16081 | NCT02650401 | Sabnis, Amit | A Phase 1/2, Open- Label, Dose- Escalation and Expansion Study of Entrectinib (RXDX-101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or Who have No Satisfactory Treamtent Options | |||
| 19082 | NCT03654716 | Vo, Kieuhoa | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | |||
| Pediatric Cancers > Rare Tumors | ||||||
| ADVL1622 | NCT02867592 | Vo, Kieuhoa | Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors | |||
| Pediatric Cancers > Relapsed/Refractory Pediatric Tumors | ||||||
| 150816 | NCT02601937 | Vo, Kieuhoa | A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | |||
| 160825 | NCT03690869 | Mueller, Sabine | A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma | |||
| 160831 | NCT03429803 | Mueller, Sabine | A Phase I Study of TAK- 580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK/ Pathway Activated Tumors | |||
| ADVL1414 | NCT02323880 | Vo, Kieuhoa | A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors | |||
| ADVL1514 | NCT02975882 | Vo, Kieuhoa | A Phase 1 Study of ABI-009 (nab-Rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan | |||
| ADVL1615 | NCT03323034 | Vo, Kieuhoa | A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors | |||
| ADVL1711 | NCT03245151 | Vo, Kieuhoa | A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors | |||
| ADVL1921 | NCT03709680 | Vo, Kieuhoa | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS | |||
| APEC1621A | NCT03213704 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions | |||
| APEC1621B | NCT03210714 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations | |||
| APEC1621C | NCT03213665 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex | |||
| APEC1621D | NCT03213678 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors | |||
| APEC1621E | NCT03213691 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations | |||
| APEC1621F | NCT03213652 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations | |||
| APEC1621G | NCT03220035 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations | |||
| APEC1621H | NCT03233204 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes | |||
| APEC1621I | NCT03526250 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes | |||
| APEC1621J | NCT03698994 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations | |||
| APEC1621SC | NCT03155620 | Rangaswami, Arun | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol | |||